Philippe Gabríel Steg
YOU?
Author Swipe
View article: Transfusion‐related adverse events in patients with restrictive or liberal transfusion strategy. An analysis of the <scp>MINT</scp> trial
Transfusion‐related adverse events in patients with restrictive or liberal transfusion strategy. An analysis of the <span>MINT</span> trial Open
Background The aim of this analysis was to quantify and compare the frequency of transfusion‐related adverse events ( TRAE ) in adult patients with myocardial infarction transfused with a restrictive versus liberal transfusion strategy fro…
View article: Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy
Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy Open
BACKGROUND: Residual cardiovascular risk remains, despite achieving low-density lipoprotein cholesterol targets with high-intensity statins. Traditional risk scores are suboptimal. This study evaluated the prognostic utility of a 9-plex ap…
View article: Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT
Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT Open
Aims We studied the efficacy and safety of icosapent ethyl (IPE) 4 g daily in reducing the risk of myocardial infarction (MI) across different MI subtypes and sizes among REDUCE-IT high-risk patients with hypertriglyceridaemia. Methods and…
View article: Comparison of cardiovascular risk in individuals with normal vs isolated elevated diastolic blood pressure
Comparison of cardiovascular risk in individuals with normal vs isolated elevated diastolic blood pressure Open
Background In 2024, the European Society of Cardiology (ESC) hypertension guidelines introduced an elevated blood pressure category, lowering the normal diastolic BP threshold from 85 to 70 mmHg. The implications of this change for risk st…
View article: Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial Open
Background In this post hoc analysis of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, we evaluated the efficacy of alirocumab in patients with probable…
View article: Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Could Acute COVID-19 Infection Ignite Thrombotic Risk? Open
With the growing body of evidence of the ischaemic and thrombotic risks associated with recent COVID-19 infection, this expert commentary reviews the data on the cardiovascular risk implications of COVID-19 and considers potential manageme…
View article: Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances
Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances Open
Importance: Extenuating circumstances can trigger unplanned changes to randomized trials and introduce methodological, ethical, feasibility, and analytical challenges that can potentially compromise the validity of findings. Numerous rando…
View article: Concept and practice in the use of high-dose eicosapentaenoic acid for cardiovascular disease prevention in hypertriglyceridaemia
Concept and practice in the use of high-dose eicosapentaenoic acid for cardiovascular disease prevention in hypertriglyceridaemia Open
Genetic and epidemiological evidence indicates that triglyceride-rich lipoproteins are causal risk factors for atherosclerotic cardiovascular disease (ASCVD). Elevated levels of plasma triglyceride are common in patients who are diabetic o…
View article: Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial
Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial Open
In a post hoc analysis of the TWILIGHT trial that included CCS patients undergoing PCI, ticagrelor monotherapy after 3 months of DAPT appeared to be safe and was not associated with increased risks of ischaemic or bleeding events, regardle…
View article: Smoking trajectories and residual cardiovascular risk in patients with stable coronary artery disease: an international cohort study
Smoking trajectories and residual cardiovascular risk in patients with stable coronary artery disease: an international cohort study Open
Aims There is a variety of smoking habits trajectories in patients with established stable coronary artery disease (CAD), with unclear consequences on cardiovascular (CV) events. We aimed to clarify the impact of smoking cessation and redu…
View article: Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES Open
Contains fulltext : 320894.pdf (Publisher’s version ) (Open Access)
View article: Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients With Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT Trial
Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients With Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT Trial Open
BACKGROUND: The MINT trial (Myocardial Ischemia and Transfusion; N=3504) randomized patients with acute myocardial infarction (MI) and hemoglobin ≤10 g/dL to liberal (maintain hemoglobin ≥10 g/dL) or restrictive (maintain hemoglobin ≥8 g/d…
View article: Credibility assessment of a mechanistic model of atherosclerosis to predict cardiovascular outcomes under lipid-lowering therapy
Credibility assessment of a mechanistic model of atherosclerosis to predict cardiovascular outcomes under lipid-lowering therapy Open
Demonstrating cardiovascular (CV) benefits with lipid-lowering therapy (LLT) requires long-term randomized clinical trials (RCTs) with thousands of patients. Innovative approaches such as in silico trials applying a disease computational m…
View article: Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial Open
Background The efficacy of icosapent ethyl among patients with very well‐controlled baseline low‐density lipoprotein cholesterol (LDL‐C) is unknown. Methods In this post hoc analysis of the REDUCE‐IT (Reduction of Cardiovascular Events Wit…
View article: Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome Open
Aims Apolipoprotein (Apo) C3 has been associated with incident coronary heart disease and major adverse cardiovascular events (MACE). Whether ApoC3 levels predict risk in patients with acute coronary syndrome (ACS) on optimized statin trea…
View article: Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial Open
OBJECTIVE Previous genetic and clinical analyses have associated lower lipoprotein(a) and LDL cholesterol (LDL-C) with greater risk of new-onset type 2 diabetes (NOD). However, PCSK9 inhibitors such as alirocumab lower both lipoprotein(a) …
View article: Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes with Alirocumab: Post-Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes with Alirocumab: Post-Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial Open
OBJECTIVEPrevious genetic and clinical analyses have associated lower lipoprotein(a) and LDL cholesterol with greater risk of new-onset type 2 diabetes (NOD). However, PCSK9 inhibitors such as alirocumab lower both lipoprotein(a) and LDL c…
View article: AMI-Sleep: protocol for a prospective study of sleep-disordered breathing/sleep apnoea syndrome and incident cardiovascular events after acute myocardial infarction
AMI-Sleep: protocol for a prospective study of sleep-disordered breathing/sleep apnoea syndrome and incident cardiovascular events after acute myocardial infarction Open
Introduction Sleep-disordered breathing (SDB) and the related clinical syndrome, sleep apnoea syndrome (SAS), are highly prevalent in patients with ischaemic heart disease and often remain undiagnosed. The AMI-Sleep study will describe its…
View article: Restrictive versus Liberal Transfusion in Myocardial Infarction — A Patient-Level Meta-Analysis
Restrictive versus Liberal Transfusion in Myocardial Infarction — A Patient-Level Meta-Analysis Open
Pooling individual patient data from four trials did not find a definitive difference in our primary composite outcome of MI or death at 30 days. At 6 months, a restrictive transfusion strategy was associated with increased all-cause morta…
View article: Association Between Body Mass Index and Clinical Outcomes in Patients with Acute Myocardial Infarction and Reduced Systolic Function: Analysis of PARADISE-MI Trial Data
Association Between Body Mass Index and Clinical Outcomes in Patients with Acute Myocardial Infarction and Reduced Systolic Function: Analysis of PARADISE-MI Trial Data Open
Aims The relationship between body mass index (BMI) and clinical outcomes in patients with cardiovascular disease, including acute heart failure (AHF) and acute myocardial infarction (AMI), remains debated. This study investigates the asso…
View article: Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial
Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial Open
BACKGROUND: The relationship between the extent and severity of stress-induced ischemia and the extent and severity of anatomic coronary artery disease (CAD) in patients with obstructive CAD is multifactorial and includes the intensity of …
View article: Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES Open
NCT01663402.